BCT 194
Alternative Names: BCT194Latest Information Update: 16 Jul 2016
At a glance
- Originator Novartis
- Class Antipsoriatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Psoriasis in Austria (Topical, Cream)
- 30 Nov 2006 Phase-I clinical trials in Psoriasis in Austria (Topical)